The FDA has announced a two-day advisory committee meeting to solicit input and advice on strategies to increase the availability of naloxone products as a way to reduce opioid overdose deaths.
The joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will take place on Dec. 17, 2018, from 8 a.m. to 5 p.m. and Dec. 18, 2018, from 8 a.m. to 4 p.m.
“At this meeting, we’ll be asking our